PRINCETON, N.J., Oct. 17 /PRNewswire-FirstCall/ -- Covance (NYSE: CVD) today achieved a successful settlement to its lawsuit against PETA, in which PETA agreed to a ban on conducting any infiltration of Covance for five years. In addition, PETA's operative, Lisa Leitten, accepted a three-year ban on infiltrating any commercial animal research facility worldwide. PETA and Leitten must also provide all video footage and written notes taken from Covance. The settlement was confirmed by the Circuit Court of Fairfax County, which entered an order requiring PETA and Leitten to comply with these requirements. "This resolution achieves our key goals of the lawsuit: to obtain a ban on infiltration and to demonstrate that Covance will not tolerate such unlawful acts by those who seek to block important biomedical research," said James Lovett, Senior Vice President and General Counsel at Covance. "The strength of our case enabled us to achieve these goals quickly via this settlement." "Our business is devoted to helping develop new medicines for diseases such as breast cancer, diabetes, leukemia, Alzheimer's, heart disease and HIV/AIDS," said Lovett. "The research we perform is essential to ensuring that these medicines are safe and effective before they are made available to patients." A copy of the settlement can be found at http://www.covance.com/animalwelfare/media-resources.php. Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1 billion, global operations in 17 countries, and more than 7,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at http://www.covance.com.